FDA approves Theravance's Vibativ for nosocomial pneumonia

Theravance obtained the FDA's approval to market its injectable antibiotic Vibativ as a treatment for hospital-acquired and ventilator-associated bacterial pneumonia caused by Staphylococcus aureus. However, the once-daily antibiotic should only be prescribed when alternative treatments cannot be used, the FDA said. Vibativ was previously approved for treatment of complicated skin and skin-structure infections.

View Full Article in:

American City Business Journals · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX